CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, the expression of genes related to the capacity of CD8+ CTLs to lyse and kill LSCs such as GrzmA and GrzmB were significantly increased in CD8+ CTLs derived from DT-treated CML mice compared with CD8+ CTLs from PBS-treated CML mice (Figure 5, H–J).